Page Title
Drug Development Pipeline
Vancomycin Inhalation Powder (AeroVanc™)
Status
DiscontinuedTherapeutic Approach
Anti-Infective
Vancomycin inhalation powder (AeroVanc™) is an inhaled dry powder version of the antibiotic vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) airway infection in people with CF.
Status
A phase 3 study of AeroVanc™ in people with CF who have Methicillin-resistant Staphylococcus aureus (MRSA) lung infection did not meet its primary endpoint of change in FEV1 (lung function). Additionally, treatment with AeroVanc did not result in a reduction in pulmonary exacerbations compared to placebo. No further development in CF is planned at this time.
Sponsor
This program is sponsored by Savara Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation. It was conducted within the Therapeutics Development Network.
Recent Vancomycin Inhalation Powder (AeroVanc™) Studies
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More